• Portfolio
    • Next Investors
    • Catalyst Hunter
    • Wise-Owl
    • Next Biotech
    • Emerge
  • Latest Articles
  • Weekenders
  • Quick Takes
  • Education
  • Trust

  • Portfolio
    • Next Investors
    • Catalyst Hunter
    • Wise-Owl
    • Next Biotech
    • Emerge
  • Latest Articles
  • Weekenders
  • Quick Takes
  • Education
  • Trust
  1. Home
  2. Cancer Treatment

Cancer Treatment

Arovella Therapeutics.png

ALA edging closer to clinical trials for “off the shelf” cell therapy cancer treatment

Next Investors Jun 27, 2023

Another month goes by, and yet another deal in the cancer cell therapy space. We Invested in Arovella Therapeutics (ASX: ALA) to see it develop and ultimately commercialise its own cell therapy cancer therapy treatment.

Arovella Therapeutics.png

ALA on the Pathway to Phase I Clinical Trials

Next Investors Apr 21, 2022

Our biotech investment, Arovella Therapeutics (ASX:ALA), is one of only a handful of companies in the world working on an iNKT cell therapy for cancer.

Placeholder Image

Could PAA’s lead cancer drug treatment treat COVID-19?

Finfeed Archived Apr 17, 2020

PharmAust Limited (ASX: PAA) has entered into a Materials Transfer Agreement with the Walter and Eliza Hall Institute of Medical Research (WEHI) to test the effects of monepantel (MPL) on COVID-19 infections.

Impedimed logo.png

ImpediMed receives order for 16 SOZO units to address lymphoedema

Finfeed Archived Apr 01, 2020

ImpediMed Limited (ASX: IPD) has received the first order of 16 units under the recently announced national purchasing agreement with a US oncology care network for its SOZO® Digital Health Platform and Lymphoedema Prevention Program.

Get expert stock analysis direct in your inbox

Join Our
Mailing List

Footer

Portfolio

  • Next Investors
  • Wise Owl
  • Catalyst Hunter
  • Next Biotech
  • Emerge

Support

  • Contact Us
  • Trust Centre
  • How it Works
  • History
  • FAQ
  • Definitions
  • Archived Articles
  • Bottom Drawer Portfolio

Policies

  • Customer Notice
  • Disclosure Policy
  • Financial Services Guide
  • ESG Policy
  • Privacy Policy

Subscribe Next Investors

Daily write ups on small cap stocks we are invested in:


Next Investors

This material has been prepared by S3 Consortium Pty Ltd (trading as StocksDigital). S3 Consortium Pty Ltd is a Corporate Authorised Representative (CAR 000433913) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.


© 2026 nextinvestors.com | All rights reserved

Follow Us